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We discussed two cases of symptomatic female carriers to Duchenne Muscular Dystrophy. The ﬁrst case
is a 20 year-old girl with classical phenotypic manifestation of the disease, similar to the condition in
boys. The case 2 is a 62 year-old woman with progressive muscular weakness. The disease is much less
common in woman than men so both cases described here are considered rare forms of the disease, with
several clinical implications. In both cases, a progressive muscle weakness, impairment in walking and
sleeping was observed, in addition to obstructive sleep apnea syndrome and alveolar hypoventilation,
that required noninvasive ventilatory support.
& 2016 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive
neuromuscular disease. This fatal disease affects approximately
1:3,500 to 6,000 live male births [1] and 1:50,000,000 live female
births [2,3]. It is a neuromuscular disorder characterized by a
mutation in the dystrophin (DMD) gene caused by deletions (65%
of cases) [4], speciﬁc mutations (26% of cases) [5], duplications (7%
of cases) [6] and other unidentiﬁed causes (about 2% of cases) [5].
In general, women with an abnormal X chromosome are
asymptomatic as long as it is compensated by the other normal
allele. Cases of DMD in which the patient develops a similar
phenotype as the male gender are rare in women [7]. Women may
be symptomatic carriers of DMD when they are affected by
homozygous mutations in the dystrophin gene, with partial or
total expression of the abnormal gene. The signs and symptoms in
women can vary from mild muscular weakness to severe clinical
complications, when the patient is deﬁned as a manifesting or
symptomatic carrier. About 20% of heterozygous female carriers
have the characteristic signs of the disease [8]. Often, carriers are
symptomatic due to chromosomal translocations, Turner syn-
drome [9,10] or abnormal X chromosome [11]. Women have two X
chromosomes and are normally not affected by X-linked disorders,
due to the capacity of the unaffected chromosome to compensateduction and Hosting by Elsevier B.
.A. Moreira).
iation of Sleep.for the deﬁciency of the abnormal gene of the other chromosome.
A number of females with X-autosome translocations with
breakpoint in the Xp21 locus have also been shown to manifest
signs and symptoms of DMD. One interpretation is that the gene
locus is in that region, and that the locus on the normal X is in-
activated, a mechanism called preferential inactivation of the X. On
rare occasions, an X chromosome may be completely missing or
present with a particular breaking point disrupting the dystrophin
gene [12].
In women, the muscle weakness is usually mild, with asym-
metric predominance and proximal distribution [13]. The onset of
symptoms in affected women is variable. It can be observed from
the ﬁrst until the fourth decade of life. It is noteworthy that those
who manifest before 15 years-old often have greater impairment
and severity of clinical manifestations [13,14]. In this study we
described two case reports of female carriers of DMD, representing
manifestations in a young and an adult women.2. Case report
2.1. Case 1
Female, single, 20 years-old, born preterm but otherwise a
normal pregnancy without complications. Parents are not con-
sanguineous and the ﬁrst case of DMD in her family. Within 18
months showed hypertrophy of the calf. At ﬁve years-old, the child
begun to show difﬁculties in getting up from the sitting positionV. This is an open access article under the CC BY-NC-ND license
Table 1
Polysomnography ﬁndings in symptomatic female carriers of Duchenne Muscular
Dystrophy.
Case 1 (PSG 1) Case 2 (PSG 1) Case 2 (PSG 2)
Total sleep time (min) 423.5 324.4 233.0
Sleep efﬁciency (%) 84.2 80.0 55.3
Sleep latency (min) 14.0 20.2 45.4
REM sleep latency (min) 81.5 351.5 –
Wake after sleep onset (min) 63.5 61.0 143.0
Arousal index (events/hour) 3.3 15.2 24.2
Stage 1 (%) 2.8 5.4 26.2
Stage 2 (%) 39.2 69.0 64.8
Stage 3 (%) 33.2 16.3 9.0










AHI (events/hour) 0.3 5.7 13.4
SpO2 o90% (min.) 4.0 1.5 26.2
Desaturation eventso3% (n) 6.3 40 57
Legend: REM¼rapid eye movement; AHI¼apnea hypopnea index; SpO2¼oxygen
saturation. Polysomnography was performed without use ventilation in all cases. In
Case 1 patient with age at 10 years old and in Case 2 patient in PSG 1 with age at 61
years old and in PSG 2 with age at 62 years old.
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course with progressive weakness in the lower limbs and foot
deformities. At nine years-old, she lost the ability to walk and
began to use a wheelchair and consequently became progressively
obese. Menarche was at ten years-old. At 10 years old, she pre-
sented complaints of dyspnea on moderate efforts, diurnal head-
ache, snoring, nocturnal sweating and witnesses apnea during
sleep. She has a complete diagnostic polysomnography (PSG) that
showed preserved sleep architecture and sleep efﬁciency (Table 1),
although mild snoring, rare hypopneas events and 0.2% of total
sleep time with SpO2 below 90% was detected. Spirometry showed
64% of forced vital capacity-FVC (1.35 L) and FVC/forced expiratory
volume (FEV1)¼101. At 11 years old patient persists with head-
ache and dyspnea. The patient had gain 10 kg of body weight.
FVC¼0.85 L (31%), FEV1¼0.83 (33%), FVC/FEV1¼98. At that mo-
ment, NIV therapy was started due to the low forced vital capacity
and symptoms. She had good adherence to the noninvasive ven-
tilation (NIV) device using it for about 6 h/night. At 11 years-old,
she was with 61 kg and 1.58 m. Three years later, she presented a
considerable weight gain, being 78.1 kg and 1.65 m, without cor-
ticoid use. At 17 years-old, she was diagnosed with dysphagia, and
consequently suffered a signiﬁcant weight loss (42.5 kg and
1.65 m). One year later this had progressed to anorexia (35 kg and
1.65 m) and underwent gastrostomy. Currently, the patient is
conﬁned to bed and receives mixed feeding (oral and gastro-
stomy). She has motor strength grade 1 in four members and ﬁ-
brous tendon retractions and uses noninvasive mechanical venti-
lation with bi-level positive airway pressure parameters in spon-
taneous/timed mode with a respiratory rate of 12 per min, in-
spiratory pressure of 16 cm H2O, expiratory pressure of 4 cm H2O,
generating tidal volumes of 200–400 mL.
The karyotype was performed by G-banding with analysis of
metaphases from temporary lymphocyte cultures of peripheral
blood. Result revealed karyotype 46,X,t(X;4)(p21;q13) [20], with a
reciprocal translocation involving the short arm of the X chro-
mosome and the long arm of one chromosome 4, with breakpoints
in Xp21 and 4q13. In addition, microarray analysis of chromosomal
aberrations and copy number variants was performed. In this case,
the test did not show copy number variations within DMD gene;however, a 471 kb duplication in the pseudoautossomal region
PAR1 (arr[hg19] Xp22.33(524,439995,018)3) was found,
overlapping the SHOX gene (OMIM #312865).
2.2. Case 2
Women, married, 62 years-old, who reported onset of weak-
ness of the muscles of the lower limbs at 56 years of age, with
progressive evolution year-by-year. Had 2 pregnancies, 1 son with
DMD, who died with aged 19 years-old, and a healthy 35 year old
daughter. Also complained of snoring, apneas, daytime sleepiness,
mood changes, morning headache, sudden awakening and frag-
mented sleep. At that time, she was taking sertraline (50 mg),
amitriptyline (25 mg), diazepam (10 mg) and metformin (500 mg).
At 61 years old, spirometry showed 83% of FVC (2.41 L) and FVC/
FEV1¼107. The PSG report showed a mild increase of the re-
spiratory disturbance index due to obstructive events, increased
N2 stage (64.8%), reduced sleep efﬁciency (80%) and REM sleep
(9.2%), mild snoring and oxygen desaturation. The oxygen desa-
turation index was more pronounced in REM sleep. End-tidal
carbon dioxide remained 166.9 min (51.4%) of total sleep time
above 50 mmHg. For this reason, mechanical ventilation was in-
dicated with bi-level positive pressure. She had good adherence to
the treatment and reported important improvement in the pre-
vious symptoms. At 62 years old, the patient was submitted to a
new PSG to monitoring since the ﬁrst polysomnography was
performed at baseline (without NIV). A new baseline poly-
somnography was performed to verify whether the patient´s
subtle symptoms reﬂect abnormal nocturnal gas exchange,
showing a slight increase in apnea-hypopnea index (13.4) due
obstructive events, and increased respiratory disturbance index
(22.1 events/hour) mainly caused by respiratory effort related to
arousal; mild to severe snoring; sleep efﬁciency reduced to 55.3%
as a result of increased sleep latency and frequent awakenings;
reduction in slow wave sleep and absence of REM sleep; increase
in arousal index (24.2 events/hour). She presented 26.2 min of
oxygen saturation below 90% (8.1% of total sleep time). Currently,
she has a myopathic gait and walks with the aid of a walking stick.
Her muscular weakness is proximal grade 4 and distal grade 5 in
her right arm, as well as proximal grade 3 and distal grade 5 in her
left lower limb. She reported the onset of severe pain in the
lumbar region, related to body posture. After a few months, she
complained of frequent falls while walking. The patient evolved
with the onset of progressive weakness in the lower limbs initially
and subsequently in the upper limbs. She reported “a trembling
sensation in the body” and chronic widespread pain. She pre-
sented other co-morbidities such as diabetes mellitus, chronic
constipation and depressive disorder.
The additional examination of karyotype by G-banding of per-
ipheral blood revealed a normal karyotype 46, XX with a resolu-
tion level of 440–550 chromosomal bands. However, through the
microarray analysis of chromosomal aberrations and copy number
variants, a duplication of exons 43–52 of the dystrophin gene was
identiﬁed, being classiﬁable as a manifesting carrier. The micro-
array test revealed two pathogenic gains in these patient, within
the DMD gene (arr[hg19] Xp21.1(31,746,94431,923,772)3 and
arr[hg19] Xp21.1(32,110,37532,328,188)3, with 177 kb and
218 kb respectively. These variants overlap exons 42–44 and 48–52
of DMD gene (OMIM #300377), respectively.3. Discussion
The patients described in this report represent uncommon
clinical manifestations in women with DMD. Case 1 is of a 20 year
old with clinical features of DMD (early symptoms since 18
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underweight. Low weight is due to severe muscle atrophy and the
consequences of dysphagia and anorexia, which possibly in-
tensiﬁed the loss of muscle mass. Body Mass Index (BMI) of this
patient was calculated from the wingspan, due to difﬁculty in
properly positioning the anthropometer. In the adult Brazilian fe-
male population, height can be estimated by dividing the wing-
span by 1.03 [18]. A severe manifestation of DMD is uncommon in
women, with mild to moderate muscular weakness only being
expected and increased creatine kinase (CK) and creatine kinase
isoform MB levels (CKMB) [19]. In case 1 in particular, the con-
centration of CK and CKMB was reduced due to severe muscle
atrophy (175 U/L and 16 U/L, respectively). The microarray did not
show copy number variations within the DMD gene; however, a
471 kb duplication in the pseudoautossomal region PAR1 (arr
[hg19] Xp22.33(524,439995,018)3) was found, overlapping
the SHOX gene (OMIM #312865). Mutations and deletions in this
gene or its 3′ regulatory region were found in 15% of patients
with idiopathic short stature, and 60% of patients with Leri-Weill
dyschondrosteosis [20]. Since this region has been described as
important to some genetic syndrome phenotypes, although not
directly involved in DMD, we cannot discard its participation in
the patient phenotype; therefore this variant was classiﬁed as a
variant of uncertain signiﬁcance. We also found a 289 kb dupli-
cation in the long arm of chromosome 10 (arr[hg19] 10q11.23
(51,874,16252,163,027)3), encompassing 4 genes (FAM21A,
FAM21B, ASAH2, SGMS1). Since this variant overlaps three DGV
entries, did not overlap any DECIPHER entry and the genes con-
tained did not show evidence for participation in DMD, this var-
iant was described as benign in relation to the DMD phenotype. In
case1, we also found a 322 kb deletion in chromosome 14 (arr
[hg19] 14q21.2 (46,638,88946,961,056)1), encompassing no
genes with only one DGV entry. Since no genes were found, to the
best of our knowledge, this variant is likely to be benign in regards
to the DMD phenotype. The microarray analysis does not show
changes in copy number, unless there is major loss or gain of ge-
netic material. In this case, the balanced translocation involving
Xp21 raises the hypothesis of a breakpoint within the DMD gene in
this segment and inactivation of the normal X chromosome. The
DMD gene is cleaved into two parts and joins another portion of
autosomal chromosome. This possibly blocks the production of a
functional protein, resulting in the classical DMD phenotype.
In the second case report, there was a signiﬁcant increase in CK
and CKMB enzymes due to the muscle degeneration (779 U/L andFig. 1. Muscle biopsy of the deltoid muscle of case 2. Legend: 1 A: ATPase 9,4 demonst
dystrophin protein expression.26 U/L, respectively). Female carriers usually have a reduction in
dystrophin and consequently mild muscle loss. The main char-
acteristics found in muscle biopsy in women with DMD is the
presence of regenerating ﬁbers with large nucleoli, necrotic ﬁbers,
increased connective tissue and ﬁber type 1 muscle ﬁbers and ﬁ-
brofatty replacement [22]. Moreover, there is a mosaic pattern
found in immunohistochemical ﬁndings with the ﬁber with nor-
mal dystrophin sarcolemma interspersed by ﬁbers with dystro-
phin deﬁciency (dystrophin positive and negative) [23]. For ethical
reasons, it was only possible to perform a biopsy on patient 2,
since the patient in case 1 had a severe clinical condition and in-
tense muscular atrophy. Muscle biopsy of the deltoid muscle in
case 2 was performed. ATPase staining in pH 9.4 identiﬁed the
presence of a slight predominance of type 1 ﬁbers (Fig. 1A). The
immunoperoxidase test showed partial expression of the protein
dystrophin (Fig. 1B). Cavalcanti and colleagues [24] observed
atrophy, variability in ﬁber size and endomysial ﬁbrosis with in-
ﬁltration of fat in their histological analysis of patients with DMD,
with a predominance of type 1 muscle. In DMD, there is a fre-
quently occurrence of progressive loss of muscle ﬁber simulta-
neous to muscle weakness and loss, as well as reduced sarco-
lemmal expression, of dystrophin in carriers [25].
The microarray study of chromosomal aberrations revealed two
pathogenic gains in patient 2, within the DMD gene (arr[hg19]
Xp21.1(31,746,94431,923,772)3 and arr[hg19] Xp21.1
(32,110,37532,328,188)3), with 177 kb and 218 kb respec-
tively. These variants overlap exons 42–44 and 48–52 of DMD gene
(OMIM #300377) respectively. Duplications found in DMD have
been described in 5–10% patients with Duchenne and Becker
muscular dystrophies [26–29]. Gains in the DMD gene were found
primarily between exons 1–7, but duplications were also found
between exons 45–55 in patients with DMD [30]. Zeng and col-
leagues [31] described 13 duplications in a total of 249 DMD pa-
tients, 7 duplications were found between exons 44–52. These
results reinforce the association between duplications in this re-
gion and phenotype expression in DMD.
During the progression of the disease, muscular weakness
worsening leading to respiratory impairment is a great landmark
in the life of patient. Consequently, the patient is forced to use
noninvasive ventilation when this weakness affects the respiratory
muscles. This impairment culminates with a decline in inspiratory
and expiratory pressures and a subsequent reduction in vital and
total lung capacity. In female carriers, muscle weakness is pre-
dominantly asymmetric, being observed 41% in the upper limbs,rated slight predominance of type 1 ﬁbers; 1B: Immunoperoxidase showed partial
K.T. Nozoe et al. / Sleep Science 9 (2016) 129–13313223% in lower limbs and 36% in both [32]. In case 1, we observed
ﬂaccid tetraparesis with grade 1 of gross motor strength, and in
case 2, proximal tetraparesis with grade 4 driving force. In both
patients there was muscle hypotonia and weakness of the re-
spiratory muscles, resulting in increased respiratory events during
sleep. The referral for PSG of the two patients was due to com-
plaints during sleep. The sleep studies observed obstructive
events, reduced sleep efﬁciency and alveolar hypoventilation in
case 2, common ﬁndings in patients with neuromuscular diseases.
During the PSG of case 2, the patient showed hypercapnia, having
51.4% of total sleep time with end-tidal CO2 above 50 mmHg. Ad-
ditionally, she presented an increased respiratory disturbance in-
dex (5.7 events/hour). This can be explained by progressive muscle
weakness, especially the respiratory muscles. When these muscles
are affected, it leads to alterations in gas exchange and conse-
quently hypercapnia and hypoxemia. For this reason, patient of
case 2 was advised to use non-invasive ventilatory support at
night. The patient had good adherence to respiratory support with
reduced daytime symptoms. Recently, this patient repeated the
PSG exam and an improvement in the hypercapnia was observed.
Nevertheless, there was an increase in respiratory disturbance
index (22.1 events/hour), probably caused by multifactorial rea-
sons related to weight gain in recent years, menopause and also by
the physical disabilities. Bi-level parameters were adjusted to
correct for these abnormalities.
Impairment in the sleep in boys with DMD is common, parti-
cularly in regard to the development of respiratory sleep disorders.
The PSG ﬁndings in both these cases are expected consequences of
disease progression. In boys with DMD, the sleep pattern and
percentage of the different sleep stages are generally not sig-
niﬁcantly compromised [33]. Generally, incidences of hypoventi-
lation [34,35], hypopnea, hypercapnia, central apnea [33] and
obstructive apnea [35] are observed. For these patients, events like
apnea become even more severe during REM sleep, because at this
stage there is a decrease in intercostal muscle tonus [36] and de-
creased activity of the muscles of the upper airways [35], in-
tensifying the consequences of hypoxia. Sleep-disordered breath-
ing causes negative repercussions on the patients´ quality of life,
such as nocturnal awakenings, daytime sleepiness and headache
[35], fatigue, dyspnea, and impaired cough mechanism [37]. In-
deed, frequent awakenings, fatigue and excessive daytime sleepi-
ness were some of the main complaints cited in both cases.
Therefore, this study suggests that symptomatic female carriers
should also be evaluated for muscle weakness and sleep impair-
ment. To provide effective treatment and appropriate health care
to the patient, the use of ventilatory support to improve the
quality of life, sleep and increased survival is essential.Funding sources
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